FMR1 and fragile X syndrome: Both baclofen and arbaclofen have been tested in Fmr1 KO mice and have been shown to reduce FXS‐related phenotypes, such as audiogenic seizures, abnormal spine morphology, synaptic protein synthesis, AMPA receptor internalization, repetitive behavior, and hyperactivity (Henderson et al., 2012; Pacey et al., 2009; Qin et al., 2015; Sinclair et al., 2017).